Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab
- 1Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Medical Student, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Division of Diagnostic Pathology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Abstract
Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein–Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.
Related
- Secondary hemophagocytic lymphohistiocytosis complicating culture-confirmed ceftriaxone-resistant Salmonella typhi infection: A rare case report.
- Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
- Hemophagocytic Lymphohistiocytosis in a Patient With Alcohol‐Associated Liver Disease: A Case Report Highlighting Diagnostic Challenges
- Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
- Successful Treatment with Rituximab in a Patient with Clinically Suspected Small-vessel Primary Central Nervous System Vasculitis Refractory to Cyclophosphamide Pulse Therapy
BibTeX
@article{ichikawa2026successful,
title = {{Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab}},
author = {Satoshi Ichikawa and Yutaka Suzuki and Yuya Tanaka and Keita Kanba and Kensuke Fujita and Yoko Okitsu and Masahiro Kobayashi and Fumiyoshi Fujishima and Junichi Kameoka and Tomonori Ishii},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = aug,
doi = {10.3960/jslrt.26032},
url = {https://doi.org/10.3960/jslrt.26032},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab
AU - Satoshi Ichikawa
AU - Yutaka Suzuki
AU - Yuya Tanaka
AU - Keita Kanba
AU - Kensuke Fujita
AU - Yoko Okitsu
AU - Masahiro Kobayashi
AU - Fumiyoshi Fujishima
AU - Junichi Kameoka
AU - Tomonori Ishii
PY - 2026
DA - 2026/08/29
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26032
UR - https://doi.org/10.3960/jslrt.26032
AB - Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein–Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.
SN - 1346-4280
SN - 1880-9952
ER -